CTCs-derived xenograft development in a Triple Negative breast cancer case

Tais Pereira-Veiga, Manuel Abreu, Diego Robledo Sanchez, Xavier Matias-Guiu, María Santacana, Laura Sánchez, Juan Cueva, Patricia Palacios, Ihab Abdulkader, Rafael López-López, Laura Muinelo-Romay, Clotilde Costa

Research output: Contribution to journalArticlepeer-review

Abstract

Triple-negative breast cancer (TNBC) is characterized by high rates of metastasis and no available molecular targets. CTCs derived xenografts (CDX) have demonstrated to be a promising tool for understanding cancer biology. In this study a CDX from a TNBC patient was developed for the first time. After CDX characterization, WNT signalling was found as the main mechanism related with this tumor biology and potential CTCs markers were identified and subsequently validated in TNBC patients. In this cohort high levels of MELK expression were associated with poorer survival rates. Overall, this study demonstrates that CTCs from TNBC are tumorigenic and CDXs are a useful model to obtain valuable information about the tumor. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalInternational Journal of Cancer
Early online date19 Nov 2018
DOIs
Publication statusE-pub ahead of print - 19 Nov 2018

Keywords

  • triple-negative breast cancer
  • Circulating Tumor Cells (CTCs)
  • CTCs-Derived xenograft (CDX)
  • metastasis

Fingerprint

Dive into the research topics of 'CTCs-derived xenograft development in a Triple Negative breast cancer case'. Together they form a unique fingerprint.

Cite this